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Abstract: 
This article describes a method developed for predicting anticancer/non-anticancer drugs using artificial neural network (ANN). 
The ANN used in this study is a feed-forward neural network with a standard back-propagation training algorithm. Using 30 
‘inductive’ QSAR descriptors alone, we have been able to achieve 84.28% accuracy for correct separation of compounds with- 
and without anticancer activity. For the complete set of 30 inductive QSAR descriptors, ANN based method reveals a superior 
model (accuracy = 84.28%, Qpred = 74.28%, sensitivity = 0.9285, specificity = 0.7857, Matthews correlation coefficient (MCC) = 
0.6998). The method was trained and tested on a non redundant data set of 380 drugs (122 anticancer and 258 non-anticancer). 
The elaborated QSAR model based on the Artificial Neural Networks approach has been extensively validated and has 
confidently assigned anticancer character to a number of trial anticancer drugs from the literature. 
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Background: 
A number of natural and synthetic products have been found 
to exhibit anticancer activity against tumor cell lines [1, 2]. 
Eventually, the number of anticancer drugs is increasing 
exponentially day by day. Hence, discrimination between 
anticancer and non-anticancer drugs is a major challenge in 
current cancer research. The worldwide pharmaceutical 
industry is investing in technologies for high-throughput 
screening (HTS) of such compounds. Therefore, development 
of  in silico techniques for anticancer drug screening is the 
demand of today’s anticancer drug discovery. The use of 
computational tools for discrimination of anticancer drugs 
from lead molecules prior to their chemical synthesis will 
accelerate the drug discovery processes in the pharmaceutical 
industry [3]. 
 
Early-phase virtual screening and compound library design 
often employs filtering routines, which are based on binary 
classifiers and are meant to eliminate potentially unwanted 
molecules from a compound library [4, 5]. Currently two 
classifier systems are most often used in these applications: 
PLS-based classifiers [6, 7] and various types of artificial 
neural networks [8, 9]. Quantitative structure activity 
relationship (QSAR) science uses a broad range of atomic and 
molecular properties ranging from merely empirical to the ‘ab 
initio’  computed. The most commonly used QSAR based 
methods can include up to thousands of descriptors readily 
computable for extensive molecular datasets. Such varieties of 
available descriptors in combination with numerous powerful 
statistical and machine learning techniques such as Artificial 
Neural Networks (ANN) allow distinguishing biologically 
active from non-active substances [10, 11]. 
 
Currently various sets of molecular descriptors are available 
[12] and thus for application to anticancer drug/non-drug 
classification of compounds, the molecules can be typically 
represented by n-dimensional vectors [10, 11]. In the current 
work, we focused on the ‘inductive’ QSAR descriptors [13] 
for anticancer/non-anticancer drug classification. These 
include various local parameters calculated for certain kinds 
of bound atoms (for instance; for most positively/negatively 
charges etc), groups of atoms (for substituent with the 
largest/smallest inductive or steric effect within a molecule) 
or computed for the entire molecule. All these descriptors 
(except the total formal charge) depend on the actual spatial 
structure of molecules. These inductive descriptors found 
broad application for quantification of antibacterial activity of 
synthetic cationic polypeptides [13]. The demand for 
computational screening methodology is clear in all areas of 
human therapeutics. However, the field of anti-cancer drugs 
has a particular need for computational solutions enabling 
rapid identification of novel therapeutic leads. QSAR 
approaches for classification of anticancer compounds against 
non-anticancer agents represents an important and valuable 
task for the modern QSAR research.  
 
The main objective of this study was to develop a scheme for 
encoding relevant information from molecular structure into a 
format which is suitable for use in ANN and to develop a Bioinformation by Biomedical Informatics Publishing Group                                open access 
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QSAR model of the binary classification of anticancer/non-
anticancer drugs with predictive capabilities, which so far has 
been unattainable. 
 
Methodology: 
Dataset 
To investigate the possibility of using the inductive QSAR 
descriptors for creation of an effective model of 
discrimination between anticancer/non-anticancer drugs, we 
have considered a dataset of 380 structurally heterogeneous 
compounds including 122 non-redundant anticancer [14, 15] 
and 258 non-redundant non-anticancer drugs. All the 122 
anticancer drugs were taken from the NCI anti-cancer agent 
mechanism database [16] and have been proved to have well 
known mechanism of action (Table 1 under supplementary 
material) whereas; all the 258 non-redundant non-anticancer 
drugs were taken from DrugBank [17]. 
 
Descriptors calculation and selection 
A set of 50 inductive descriptors have been calculated initially 
for all the 380 drugs. During calculation the hydrogen atoms 
were suppressed and only the heavy atoms have been taken 
into account. The inductive QSAR descriptors were calculated 
from values of atomic electro-negativities and radii by using 
the custom SVL-scripts downloaded from the SVL exchanger 
[18] and implemented within the MOE package (Chemical 
Computing Group Inc 2005). To avoid cross correlation 
among the independent variables, we have computed pair-
wise correlation among all the 50 QSAR parameters and 
removed those inductive descriptors which formed any linear 
dependence with R ≥ 0.9. As a result of this procedure, only 
30 inductive QSAR descriptors have been selected (Table 2 
see supplementary material). The normalized values (in the 
scale of 0-1) of these 30 parameters have been used to 
generate QSAR models.  
 
Composition of the training and testing sets  
For effective training of the network (primarily to avoid over-
fitting), we have used the training sets of 342 compounds 
(including 100 anticancer drugs) randomly derived out of the 
380 molecules. Such random sampling has been performed 20 
times and 20 independent QSAR models have been created. 
In each training run the remaining 10 percent of the 
compounds were used as the testing set in order to evaluate 
the average predictive ability of the method. The given 
performance measures have been averaged over five QSAR 
models. 
 
ANN model for classification of anticancer/non-anticancer 
drugs 
In order to relate the inductive descriptors to anticancer 
activity of the studied molecules we have employed the 
standard back-propagation ANN using Stuttgart Neural 
Network Simulator package [19]. The ANN used in this study 
consists of 30 input nodes, depicting 30 inductive QSAR 
descriptors and 1 output node. The number of nodes in the 
hidden layer varied from 2 to 40 in order to find the optimal 
network that allows most accurate separation of 
anticancer/non-anticancer drugs in the training sets. During 
the learning phase, a value of 1 was assigned for the 
anticancer drugs and 0 to the others. For each configuration of 
the ANN (with 2, 4, 6, 8, 10, 12, 14, 20 and 40 hidden nodes 
respectively) 20 independent training runs were performed to 
evaluate the average predictive power of the network. The 
corresponding counts of the true positive, true negative, false 
positive and false negative predictions have been estimated 
using 0.4 and 0.6 cut-off values for non-anticancer and 
anticancer respectively. Thus, an anticancer drug from the 
testing set has been considered classified correctly by the 
ANN only when its output value ranged from 0.6 to 1.0. 
Similarly, for each non-anticancer drug of the testing set, the 
correct classification has been obtained if the ANN output lay 
between 0 and 0.4. Thus, all network output values ranging 
from 0.4 to 0.6 have been ultimately considered as incorrect 
predictions (rather than undetermined or non-defined). 
 
Performance measures 
The prediction results from neural network model were 
evaluated using the following statistical measures like 
accuracy, Matthews correlation coefficient (MCC), sensitivity 
(Qsens), specificity (Qspec), probability of correct prediction 
(Qpred) by using the equations given under supplementary 
material.  
  
Results and discussion: 
The accuracy of distinguishing of anticancer compounds by 
the artificial neural networks built upon the ‘inductive’ 
descriptors clearly demonstrates the adequacy and good 
predictive power of the developed QSAR model. There is 
strong evidence that the introduced inductive descriptors do 
adequately reflect the structural properties of chemicals, 
which are relevant to their anticancer activity. This 
observation is not surprising, considering the inductive QSAR 
descriptors calculated should cover a very broad range of 
proprieties of bound atoms and molecules related to their size, 
polarizability, electro-negativity, compactness, mutual 
inductive, steric influence and distribution of electronic 
density, etc. The average value for both the classes were 
separated to quite an extent on the graph and the selected 30 
inductive descriptors should allow building of an effective 
QSAR model for binary classification.  
 
Considering the most important implication of the 
“anticancer-likeness” model is its potential use for 
identification of novel anticancer drug candidates from 
electronic databases, we have calculated the parameters of the 
positive predictive values (PPV) for the networks while 
varying the number of hidden nodes. Taking into account the 
PPV values for the networks with the varying number of the 
hidden nodes along with the corresponding values of 
sensitivity, specificity and general accuracy, we have selected 
neural network with six hidden nodes as the most efficient 
among the studied ANNs (Table 2 in supplementary 
material). The ANN with 30 input, 6 hidden and 1 output 
nodes has allowed the recognition of 84% of anticancer and 
84% of non-anticancer compounds on average. The output 
from this 30-6-1 network has also demonstrated very good 
separation on positive (anticancer) and negative (non-Bioinformation by Biomedical Informatics Publishing Group                                open access 
www.bioinformation.net                                                                Hypothesis 
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anticancer) predictions, which revealed a superior model 
(accuracy = 84.28%, Qpred = 74.28%, sensitivity = 0.9285, 
specificity = 0.7857, Matthews correlation coefficient (MCC) 
= 0.6998) (Table 2 in supplementary material). The vast 
majority of the predictions for the testing sets consisting of ⅓ 
of anticancer and ⅔ of non-anticancer compounds, has been 
contained within 0.0 - 0.4 for non-anticancer and 0.6 - 1.0 for 
anticancer drugs which also illustrates that 0.4 and 0.6 cut-off 
values provide very adequate separation of two bioactive 
classes (Table 3 and 4 (see supplementary material) feature 
the output values from the 30-6-1 ANN for the training and 
testing sets respectively). Presumably, accuracy of the 
approach operating by the inductive descriptors can be 
improved even further by expanding the QSAR descriptors or 
by applying more powerful classification technique such as 
Support Vector Machine. Use of merely statistical techniques 
in conjunction with the inductive QSAR descriptors would 
also be beneficial, as they allow interpreting individual 
descriptor contributions into molecular “anticancer-likeness”. 
Nonetheless, despite certain drawbacks, it is obvious that the 
developed ANN-based QSAR model operating by the 
inductive descriptors has demonstrated very high accuracy 
and can be used for mining electronic collections of chemical 
structures for novel anticancer candidates. 
 
An application of the model 
The developed QSAR model of distinguishing anticancer 
drugs was validated further based on the anticancer 
compounds published in the journal ‘Nature Review Drug 
Discovery’, July 2004, spplement HOT DRUGS 2004; and 
‘Current Pharmaceutical Design’, 2000. The “experimental” 
anticancer drugs cited by the Nature Review includes 
Gefitinib (an inhibitor of Tyrosine Kinase) and Abarelix 
(inhibit production of androgens involved in prostrate cancer). 
The drugs Etoposide and Teniposide and their involvement in 
cancer treatments are published in Current Pharmaceutical 
Design [20]. The corresponding structural formulas and their 
prediction results as anticancer drugs were presented in Table 
6 under supplementary material. The predicted output of all 
the 12 drugs was above 0.60, the threshold value for 
predicting as anticancer drugs by the model. These results 
demonstrate that the ANN-based binary classifier of 
anticancer/non-anticancer drugs is adequate and can be 
considered an effective tool for ‘in silico’ anticancer drugs 
screening. The results also demonstrate that the inductive 
parameters readily accessible from atomic electronegativities, 
covalent radii and interatomic distances can produce a variety 
of useful QSAR descriptors to be used in ‘in silico’ chemical 
research. 
 
Conclusion: 
The results of the present work demonstrate that a variety of 
atomic, substituent and molecular properties which can be 
computed within the framework of inductive and steric 
effects, inductive electro-negativity and molecular 
capacitance represent a powerful arsenal of 3D QSAR 
descriptors for modern ‘in silico’ drug research. Using only 
30 inductive descriptors with no additional independent 
parameters, we have achieved 84.28% accuracy for 
distinguishing compounds with and without anticancer 
activity. The selected set of inductive descriptors possesses a 
number of important merits. They are 3D and stereo-sensitive 
which can be easily computed from fundamental properties of 
bound atoms and molecules and possess much defined 
physical meaning. This ANN-based model for anticancer drug 
prediction can be used as a powerful QSAR tool for filtering 
out lead molecules to discover novel anticancer drugs. 
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Supplementary material 
 
Equations 
Accuracy (QACC)      QACC = (TP + TN) / (TP + TN + FP + FN)  → (1) 
where TP, FP, TN and FN refer to true positives, false positives, true negatives and false negatives, respectively.  
 
Matthews correlation coefficient 
(MCC) 
 
→ (2) 
Sensitivity (Qsens)    Qsens = TP / (TP + FN) 
  → (3) 
Specificity (Qspec)    Qspec = TN / (TN + FP) 
  →  
(4) 
Probability of correct prediction 
(Qpred) 
Qpred = (TP / (TP + FP)) x 100  → (5) 
      
 
Tables 
Anti-cancer drugs by mechanism  Number of drug molecules 
Alkylating agents  36 
Antimitotic agents  13 
Topoisomerase I inhibitors  24 
Topoisomerase II   15 
inhibitorsRNA/DNA antimetabolites  18 
DNA antimetabolites  16 
Total  122 
Table 1: A dataset of 122 anti-cancer drugs used in the study with their mechanism of action. 
 Descriptor    Characterization   Descriptor    Characterization 
Average_EO_Pos 
 
arithmetic mean of electronegativities of 
atoms with positive partial charge 
 
Most_Pos_Rs_i_mol 
 
Steric influence 
Rs(atom→molecule) 
OF the most positively charged 
atom to the rest of a molecule 
Average_Hardness 
 
arithmetic mean of hardnesses of all 
atoms of a molecule 
 
Most_Pos_Sigma_i_mol 
 
 
Largest positive atomic inductive  
parameter σ*(atom→molecule) 
for 
atoms in a molecule 
Average_Neg_Charge* 
 
Arithmetic mean of negative partial 
charges on atoms of a molecule 
Smallest_Neg_Softness 
 
Smallest atomic softness among  
values for negatively charged 
atoms 
Average_Neg_Hardness  
 
arithmetic mean of hardnesses of atoms 
with negative partial charge 
Smallest_Pos_Hardness 
 
Smallest atomic hardness among  
values for positively charged 
atoms 
Average_Neg_Softness 
 
Arithmetic mean of softnesses of atoms 
with negative partial charge 
Smallest_Pos_Softness 
 
Smallest atomic softness among  
values for positively charged 
atoms 
Average_Pos_Charge* 
 
Arithmetic mean of positive partial 
charges on atoms of a molecule 
Smallest_Rs_i_mol 
 
 
Smallest value of atomic steric 
influence Rs(atom→molecule) in 
a 
molecule 
Average_Pos_Softness 
 
Arithmetic mean of softnesses of atoms 
with positive partial charge 
Smallest_Rs_mol_i* 
 
 
Smallest value of group steric 
influence Rs(molecule→atom) in 
a 
molecule 
Largest_Neg_Hardness*  Largest atomic hardness among values  Softness_of_Most_Neg  Atomic softness of an atom with Bioinformation by Biomedical Informatics Publishing Group                                open access 
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Table 2: The thirty ‘Inductive QSAR Descriptors’ used in the study. 
 
Hidden 
nodes 
Specificity Sensitivity  Accuracy 
Q(Total) 
Q (Pred in %)  MCC 
2  0.7674  0.9259 0.8285 71.42  0.6750 
4  0.7674  0.9259 0.8285 71.42  0.6750 
6  0.7857  0.9285 0.8428 74.28  0.6998 
8  0.7674  0.9259 0.8285 71.42  0.6750 
10  0.7674  0.9259 0.8285 71.42  0.6750 
12  0.7500  0.9230 0.8142 68.57  0.6504 
14  0.7500  0.9230 0.8142 68.57  0.6504 
20  0.7500  0.9230 0.8142 68.57  0.6504 
40  0.7500  0.9230 0.8142 68.57  0.6504 
Table 3: Parameters of specificity, sensitivity, accuracy and positive predictive values for prediction of anticancer and non-
anticancer compounds by the artificial neural networks with the varying number of hidden nodes. The cut-off values 0.4 and 
0.6 have been used for negative and positive predictions respectively. 
 
Name Output  Name  Output 
Anticancer   Maytansine  0.850 
asaley 0.973  Rhizoxin  0.981 
busulfan 0.702 carboxyphthalatoplatinum  0.982 
Thiopurine 0.881  Taxol  derivative  0.733 
CBDCA 0.938 chlorozotocin  0.606 
CCNU 0.825  cis-platinum  0.983 
CHIP 0.977  clomesone  0.770 
Taxol 0.920  Vincristine  sulfate  0.984 
cyclodisone 0.926  Camptothecin  0.974 
dianhydrogalactitol 0.604  Camptothecin Na salt  0.970 
fluorodopan 0.985  Aminocamptothecin  0.938 
hepsulfam 0.974  Hydroxycamptothecin  0.860 
  for negatively charged atoms 
 
 
 
the most negative charge 
Largest_Rs_i_mol 
 
Largest value of atomic steric 
influence Rs(atom→molecule) in a 
molecule 
Softness_of_Most_Pos 
 
Atomic softness of an atom with 
the 
most positive charge 
Most_Neg_Charge 
 
Largest partial charge among values for 
negatively charged atoms 
Sum_Hardness* 
 
Sum of hardnesses of atoms of a 
molecule 
 
Most_Neg_Rs_i_mol 
 
Steric influence Rs(atom→molecule) 
OF the most negatively charged atom to 
the rest of a molecule 
Sum_Neg_Hardness 
 
Sum of hardnesses of atoms with 
negative partial charge 
 
Most_Neg_Rs_mol_i* 
 
Steric influence Rs(molecule→atom) 
ON the most negatively charged atom in 
a molecule 
Sum_Pos_Hardness 
 
Sum of hardnesses of atoms with 
positive partial charge 
 
Most_Neg_Sigma_i_mol* 
 
Largest negative atomic inductive 
parameter σ*(atom→molecule) for 
atoms in a molecule 
 
 
Sum_Neg_Sigma_mol_i* 
 
Sum of all negative group 
inductive 
parameters σ*( molecule 
→atom)within a molecule 
Sum_Neg_Sigma_mol_i* 
 
 
Sum of all negative group inductive 
parameters σ*( molecule →atom) 
within a molecule 
Total_Charge_Formal* 
 
Sum of charges on all atoms of a 
molecule (formal charge of a 
molecule) 
Most_Pos_Charge* 
 
Largest partial charge among values for 
positively charged atoms 
Total_Neg_Softness* 
 
Sum of softnesses of atoms with 
negative partial charge Bioinformation by Biomedical Informatics Publishing Group                                open access 
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hycanthone 0.982  Camptothecin  acetate  0.915 
melphalan 0.985  14-Chloro-20(S)-camptothecin hydrate  0.973 
Methyl CCNU  0.985  9-Amino-20-(R,S)-camptothecin  0.984 
Mitomycin C  0.984  Camptothecin analog  0.630 
Piperazine 0.978  7-Chlorocamptothecin 0.963 
Piperazinedione 0.979  Camptothecin analog-monohydrochloride  0.967 
Pipobroman 0.984  Camptothecin,20-O-((4-(2-hydroxyethyl)-1-
piperazino)OAC 
0.980 
Porfiromycin 0.980  Camptothecin,  9-methoxy-  0.955 
GLYCINATE 0.847  Camptothecin,  4-ethyl-4-hydroxy-11-methoxy  0.983 
Teroxirone 0.960  11-Formyl-20(RS)-camptothecin  0.901 
Tetraplatin 0.976  11-Hydroxymethyl-20(RS)-camptothecin 0.700 
Thio-tepa 0.966  Camptothecin  phosphate  0.850 
PALA 0.786  Camptothecin-20-O-(N,N-dimethyl)glycinate HCl  0.577 
m-AMSA  0.658  Camptothecin lysinate HCl  0.962 
Yoshi-864  0.919  Camptothecin glutamate HCl  0.971 
Colchicines 0.919  Camptothecin  butylglycinate ester hydrochloride  0.907 
Mitoxantrone 0.938  Camptothecin  hemisuccinate sodium salt  0.946 
Dolastatin 10  0.963  Spirohydantoin mustard  0.984 
menogaril 0.600  Camptothecin  ethylglycinate ester hydrochloride  0.965 
Oxanthrazole 0.694  Morpholino-ADR  0.984 
Rubidazone 0.791  Halichondrin  b  0.951 
VM-26 0.723  Amonafide  0.977 
VP-16 0.981  Uracil  nitrogen  mustard  0.979 
L-alanosine 0.736  Anthrapyrazole derivative  0.665 
5-azacytidine 0.636  Pyrazoloacridine  0.975 
Acivicin 0.705 Bisantrene  HCL  0.970 
An antifol  0.901  Daunorubicin  0.980 
3-HP 0.978  Deoxydoxorubicin  0.983 
Pyrazofurin 0.912  Colchicines  derivative  0.975 
Name Output  Name  Output 
Trimetrexate 0.822  N,N-dibenzyl  daunomycin  0.884 
Ara-C  0.909  L-Aspartic acid, aminopterine,   0.895 
Beta-TGDR 0.963  L-Aspartic  acid,  aminopterine- sesquihydrate  0.915 
cyclocytidine 0.983  Aspartic  acid, N-[2-chloro-4-[[(2, 4-diamino-6-
pteridinyl)methyl]amino]benzoyl]-, monohydrate, L-  
0.955 
Guanazole 0.911  Baker’s  soluble  antifol  0.971 
hydroxyurea 0.983  Dichlorallyl  lawsone  0.937 
Macbecin II  0.837  Aphidicolin glycinate  0.929 
pyrazoloimidazole 0.942  5-aza-2’-deoxycytidine  0.873 
Thioguanine 0.739  5,6-dihydro-5-azacytidine 0.938 
5-HP 0.850  Methotrexate  derivative  0.857 
Alpha-TGDR 0.882  cyanomorpholinodoxorubicin  0.908 
Alpha-TGDR 0.954  2’-deoxy-5-fluorouridine  0.915 
Brequinar 0.924  Inosine  glycodialdehyde   
Ftorafur 0.943  Triethylenemelamine   
Non-anticancer       
2-amino-4-picoline 0.258  5-bromosalicylic acid acetate  0.258 
bezafibrate 0.256  5-nitro-2propoxyacetanilide  0.280 
binifibrate 0.319  5-nitro-2propoxyacetanilide  0.258 
bisoprolol 0.184  acecarbromal  0.431 
bitolterol 0.004 aceclofenac  0.258 
bucloxic acid  0.258  acefylline(c,d,e,g)  0.541 
Bromfenac 0.258  emorfazone  0.348 
bufexamac 0.327  bromisovalum  0.258 
Alphaprodine 0.108  bromodiphenhydramine 0.057 
Alprenolol 0.249  acetylsalicylic  acid  0.158 
Amosulalol 0.328  alminoprofen  0.248 
Anileridine 0.218  Bufuralo  0.008 Bioinformation by Biomedical Informatics Publishing Group                                open access 
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Antipyrine 0.168  Bunitrolol  0.238 
Antrafenine 0.258  Bumadizon  0.418 
Apazone 0.290 Butallylonal  0.032 
Apronalide 0.259  Butanilicaine  0.293 
Bamifylline 0.257  Butibufen  0.258 
Capuride 0.066 butidrine  hydrochloride  0.015 
carbiphene   0.258  Butoctamide  0.255 
carbocloral 0.313  diethylbromoacetamide  0.031 
carbromal 0.257  difenpiramie  0.004 
carbuterol 0.258  diflunisal  0.258 
carfimate 0.263  dilevalol  0.162 
carprofen 0.258  dioxadrol  0.279 
carteolol 0.000 dipyrocetyl  0.000 
carvedilol 0.259  carsalam  0.004 
doxofylline 0.255  celiprolol  0.001 
droperidol 0.000  cetirizine  0.258 
dyphylline 0.315  chlorobutanol  0.311 
Name Output  Name  Output 
chlorothen 0.001  dipyrone  0.001 
chlorprothixene 0.041  doxefazepam  0.002 
chlorcyclizine 0.270  ephedrine  0.258 
cinmetacin 0.410  eprozinol  0.259 
embramine 0.244  Etafedrine    0.335 
enfenamic acid  0.010  etaqualone  0.258 
epanolol 0.256 etersalate  0.259 
epirizole 0.246 ethinamate  0.258 
estazolam 0.258  ethoxazene  0.004 
etamiphyllin 0.229  ciprofibrate  0.261 
eterobarb 0.237  clenbuterol  0.261 
ethenzamide 0.002  clinofibrate  0.179 
ethoheptazine 0.050  clometacin  0.323 
cinromida 0.070  clonixin  0.259 
clemastine 0.095  clordesmetildiazepam 0.783 
clidanac 0.017 cropropamide  0.259 
clofibric acid  0.258  fentanyl  0.213 
clometiazol 0.078  floctafenine  0.000 
cloranolol 0.251  fluoresone  0.289 
clozapine 0.248  lornoxicam  0.258 
fluphenazine 0.039  loxoprofen  0.256 
loxapina 0.234 medibazine  0.000 
mecloqualone 0.258  formoterol  0.095 
flupirtine 0.282  flurazepam  0.481 
flutropium bromide  0.255  fluspirilene  0.005 
fluproquazone 0.256  medrylamine  0.214 
flurbiprofen 0.292  mepindolol  0.256 
methafurylene 0.179  mequitazine  0.260 
methyltyrosine 0.260  methaphenilene 0.512 
metiapine 0.003  methyldopa  0.611 
metofoline 0.051  gentisic  acid  0.337 
metron 0.002  glucametacin  0.254 
pyrilamine 0.348  haloperidide 0.180 
hydroxyzine 0.035  hexapropymate  0.126 
ibuprofen 0.005  methyldopa  0.003 
indenolol 0.262  methyprylon  0.250 
isoetharine 0.002  metipranolol  0.259 
morazone 0.258  metoprolol  0.252 
moxastine 0.030  mexiletine  0.068 
naproxen 0.058  pyrrobutamine  0.218 
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isonixin 0.254  ibuproxam  0.255 
isoxicam 0.258 fosazepam  0.254 
ketorolac 0.229  meparfynol  0.257 
indomethacin 0.258  meprobamate 0.000 
Name Output  Name  Output 
octopamine 0.260  ipratropium  bromide  0.000 
oxaceprol 0.260  morphine  0.259 
oxanamide 0.258  nadoxolol  0.284 
oxitropium bromide  0.260  narcobarbital  0.254 
propyphenazone 0.101  orphenadrine  0.331 
reprotero 0.000 oxametacine  0.000 
proxibarbital 0.031  oxaprozin  0.296 
phenacetin 0.013  oxprenolol  0.258 
pindolol 0.258 protokylol  0.259 
piperidione 0.257  salicylamide O-acetic acid  0.435 
tertatolol 0.438 proxyphylline  0.258 
thenyldiamine 0.008  phenylbutazone 0.127 
tiaprofenic acid  0.237  phenyltoloxamine(a,c,g)  0.254 
toliprolol 0.245  pipebuzone  0.001 
tolmetin 0.399 thenaldine  0.003 
tolpropamine 0.207  theobromine  0.276 
trifluperidol 0.008  procaterol  0.298 
trimethadione 0.258  prolintane  0.248 
zolamine 0.251 pronethalol  0.002 
thioridazine 0.003  tripelennamine  0.099 
triazolam 0.148  tulobuterol  0.034 
triclofos 0.034 vinylbital  0.284 
trifluoperazine 0.363  xibenolol  0.343 
zomepirac 0.247     
Table 4: Compounds of the training set and output values from the trained neural network with six hidden nodes. 
 
Name Output  Name  Output 
Anticancer 
AZQ 0.984  methotrimeprazine  0.117 
BCNU 0.881  gemfibrozil  0.001 
Thiocolchicine 0.924  glafenine  0.260 
Trityl cysteine  0.730  glutethimide  0.000 
Vinblastine sulfate  0.685  haloperidol  0.248 
chlorambucil 0.984  hexobarbital  0.259 
Mitozolamide 0.874  isofezolac  0.259 
Nitrogen mustard  0.985  isopromethazine  0.265 
PCNU 0.946  ketoprofen  0.221 
Aminopterin   0.848  labetalol  0.000 
methotrexate 0.912  niceritrol  0.260 
Allocolchicine 0.880  nifenalol  0.262 
Doxorubicin 0.984  probucol  0.133 
Non-anticancer  proglumetacin 0.000 
acetanilide 0.023  promazine  0.260 
acetazolamide 0.263  propanolol  0.260 
bucetin 0.227  thiothixene  0.292 
bufetolol 0.148  thonzylamine  0.269 
Butofilolol 0.252  timolol  0.358 
Carbidopa 0.257  tretoquinol  0.356 
Arotinolol 0.159  triprolidine  0.129 
cetamolol 0.257  viminol  0.257 
chlorhexadol 0.006  xenbucin  0.214 
chloropyramine 0.009  salsalate  0.003 
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doxylamine(b,f,g,i) 0.000  secobarbital  0.001 
droxicam 0.256  Phenopyrazone  0.258 
ectylurea 0.232  pirprofen  0.418 
chlorpheniramine 0.002  lefetamine  0.006 
chlorthenoxacin 0.258  nicoclonate  0.266 
cinchophen 0.094  nipradilol  0.259 
cinnarizine 0.130  nordiazepam  0.459 
moprolol 0.259  nitrazepam  0.210 
enprofylline 0.248  novonal  0.282 
fenoterol 0.388  salacetamide  0.684 
fentiazac 0.197  salicylamide 0.254 
flufenamic acid  0.251  phenoperidine  0.258 
meclofenamic acid(f)  0.265  piroxicam  0.000 
ronifibrate 0.259     
Table 5:  Compounds of the testing set and the corresponding output values from the trained neural network with six hidden 
nodes. 
 
Compound name  Structure  Compound ID 
(Drug bank ID) 
Prediction 
Etoposide 
                        
APRD00239 0.999 
Teniposide 
              
APRD00649 1.000 
Abarelix 
             
BTD00051 1.000 
Gefitinib 
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Erlotinib 
                 
APRD00951 0.982 
Imatinib (tyrosine 
kinase inhibitor) 
                
APRD01028 0.985 
Tamoxifen (estrogen 
receptor inhibitor) 
 
          
APRD00123 0.985 
Daunorubicin 
(inhibit DNA 
synthesis by 
intercalating with 
base pair) 
 
              
APRD00521 0.984 
Idarubicin (antitumor 
antibiotic) 
 
             
APRD00126 0.915 
Mitoxantrone 
(type II 
topoisomerase 
inhibitor) 
            
APRD00371 0.985 
Camptothecin 
(Topoisomerase I 
inhibitor) 
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aclitaxel 
(Antimitotic agent) 
APRD00259 0.994 
Table 6: Structural formulas and prediction results from the neural network for some anticancer drugs (validation set). 
 